RxDoctor Payments Data

Eve Shapiro

Pediatrics · Tucson, AZNPI 1376530907

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $364 of the $421 with a category attached, or 86.4%. 6 manufacturers reported payments, led by AstraZeneca at 43.4% of the total. Reporting peaked in 2023 at $204 and has fallen 75.1% since, to $51 in 2025.

$421in general payments, 2019–2025

Across 13 payments — averaging $32.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$183
  • Amgen$93
  • Sanofi$51
  • Merck$37
  • Cranial Technologies, Inc$33
  • Genentech USA, Inc.$24
$4,369,882in research payments, 2019–2025

Across 186 payments — averaging $23,494 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$3M
  • Amgen$504K
  • Sanofi US Services Inc.$228K
  • AstraZeneca$144K
  • AbbVie$102K
  • Merck$96K
  • plus $332K from 10 others

What the payments were for

  • Travel & lodging$5714%
  • Food & beverage$36486%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$421 in reported general payments places this provider in the 65th percentile of 1,073 pediatrics providers in Arizona.

See all pediatrics providers in Arizona

Other pediatrics in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →